AI-generated summary
The authors report a prospective trial of photodynamic therapy with porfimer sodium and 630 nm light in 30 patients with oral or laryngeal dysplasia, carcinoma in situ, or early carcinoma, of whom 26 were evaluable. Most patients (24 of 26) had a complete response at follow-up averaging 15 months, and temporary side effects such as edema and pain were reported. The authors conclude the treatment is an effective alternative with no permanent sequelae.
- Participants
- 30
- Who or what was studied
- Patients with primary or recurrent moderate to severe oral or laryngeal dysplasia, carcinoma in situ, or T1N0 carcinoma at a National Cancer Institute-designated cancer institute
- Wavelengths
- 630 nm
- Limits stated in the abstract
- The abstract describes a single-arm prospective trial without a control group, with only 26 of 30 patients evaluable and three recurrences among those with an initial complete response.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on archotol.jamanetwork.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 630 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Photodynamic therapy, Laser, Trial registration, Dose. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.